翻訳と辞書
Words near each other
・ "O" Is for Outlaw
・ "O"-Jung.Ban.Hap.
・ "Ode-to-Napoleon" hexachord
・ "Oh Yeah!" Live
・ "Our Contemporary" regional art exhibition (Leningrad, 1975)
・ "P" Is for Peril
・ "Pimpernel" Smith
・ "Polish death camp" controversy
・ "Pro knigi" ("About books")
・ "Prosopa" Greek Television Awards
・ "Pussy Cats" Starring the Walkmen
・ "Q" Is for Quarry
・ "R" Is for Ricochet
・ "R" The King (2016 film)
・ "Rags" Ragland
・ ! (album)
・ ! (disambiguation)
・ !!
・ !!!
・ !!! (album)
・ !!Destroy-Oh-Boy!!
・ !Action Pact!
・ !Arriba! La Pachanga
・ !Hero
・ !Hero (album)
・ !Kung language
・ !Oka Tokat
・ !PAUS3
・ !T.O.O.H.!
・ !Women Art Revolution


Dictionary Lists
翻訳と辞書 辞書検索 [ 開発暫定版 ]
スポンサード リンク

DPP-4 inhibitor : ウィキペディア英語版
Dipeptidyl peptidase-4 inhibitor

Inhibitors of dipeptidyl peptidase 4, also DPP-4 inhibitors or gliptins, are a class of oral hypoglycemics that block DPP-4. They can be used to treat diabetes mellitus type 2.
The first agent of the class - sitagliptin - was approved by the FDA in 2006.〔

Glucagon increases blood glucose levels, and DPP-4 inhibitors reduce glucagon and blood glucose levels. The mechanism of DPP-4 inhibitors is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.
A recent meta analysis found no favorable or harmful effect of DPPIV inhibitors on all-cause mortality, cardiovascular mortality, or stroke, but a marginally statistically significant increase in heart failure.
==Examples==
Drugs belonging to this class are :
* Sitagliptin (FDA approved 2006, marketed by Merck & Co. as Januvia),
* Vildagliptin (EU approved 2007, marketed in the EU by Novartis as Galvus),
* Saxagliptin (FDA approved in 2009, marketed as Onglyza),
* Linagliptin (FDA approved in 2011, marketed as Tradjenta by Eli Lilly Co and Boehringer Ingelheim),
* Anagliptin (approved in Japan in 2012, marketed by Sanwa Kagaku Kenkyusho Co., Ltd. and Kowa Company, Ltd.)〔http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2012.pdf〕
* Teneligliptin (approved in Japan in 2012)
* Alogliptin (FDA approved 2013, marketed by Takeda Pharmaceutical Company)
* Trelagliptin, approved for use in Japan in 2015
* Gemigliptin (being developed by LG Life Sciences)〔(【引用サイトリンク】title=LG Life Science )
* Dutogliptin (being developed by Phenomix Corporation), Phase III〔"Forest Splits With Phenomix", San Diego Business Journal, Tuesday, April 20, 2010 http://www.sdbj.com/news/2010/apr/20/forest-splits-phenomix/〕
* Omarigliptin (MK-3102) (approved in Japan in 2015, developed by Merck & Co., research showed that omarigliptin can be used as once-weekly treatment and generally well-tolerated throughout the base and extension studies〔(【引用サイトリンク】 title=Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes )〕)
Other chemicals which inhibit DPP4 include:
* Berberine, the common herbal dietary supplement, too inhibits dipeptidyl peptidase-4, which at least partly explains its antihyperglycemic activity.
* Lupeol, found in mango, red alder (Alnus rubra), and dandelion coffee.

抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)
ウィキペディアで「Dipeptidyl peptidase-4 inhibitor」の詳細全文を読む



スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース

Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.